• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·3341.T
Share

NIHON CHOUZAI Co.,Ltd. Stocks

¥ 3930Last Updated 18.12.2025

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

¥ 733.62M

¥ 3930
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Poor growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Nihon Chouzai Co., Ltd. engages in the management of health insurance dispensing chain pharmacies in Japan. The company also manufactures and sells generic drugs to medical institutions and other pharmacies. In addition, it offers temporary staffing services for pharmacist; and employment services for physicians and registered sales personnel, and other healthcare professionals. Further, the company provides studies and research services for pharmaceutical companies and organizations; information and consulting services for industries associated with pharmaceuticals and healthcare; and other services. As of March 31, 2022, it had 697 stores. The company was incorporated in 1980 and is headquartered in Tokyo, Japan.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value on EV/

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of 3341.T is 1555 and suggests 60% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.07.2026 09:00

"Mag7 is dead as a concept": Citi sees new leaders in the "growth cluster"

21.07.2026 08:00

Boeing has edged out Airbus in the battle for orders, but is trailing in the race for a new aircraft

21.07.2026 07:00

The Houthis Want to Block the “Second Strait of Hormuz”: Three Questions About the New Threat to Oil Prices

21.07.2026 04:00

SpaceX lost more than $1 trillion in market value in a month

21.07.2026 03:16

From hockey sticks to cement: The U.S. imposes 50 percent tariffs on imports from Canada

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026